Fluid Biomed key facts
as of Oct 2026- Developer of polymer-based medical devices designed to commercialize the next generation of stents to heal blood vessels.
- Fluid Biomed is valued at approximately $3.9M as of Oct 2026 (last reported valuation).
- It has raised $32.5M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Creative Destruction Lab, MedTech Innovator, Amino Capital, IAG Capital Partners, ShangBay Capital — 24 tracked in total.
- Status: Privately Held (backing).
Fluid Biomed's last reported valuation, Dec 2019. Nothing priced has surfaced since.
- ·The complete investor list: 24 names
- ·Watch Fluid Biomed: the Monday email on marks, rounds and moves
Fluid Biomed funding rounds
No funding rounds for Fluid Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Fluid Biomed
24+Fluid Biomed valuation
Fluid Biomed's last reported valuation was $3.9 million in Dec 2019. No priced round, secondary trade or fund mark has surfaced since.
Fluid Biomed investors
24 investors are on record for Fluid Biomed, including Creative Destruction Lab, MedTech Innovator, Amino Capital and IAG Capital Partners. By type, the record holds 4 venture capital firms and 1 family office.
About Fluid Biomed
Developer of polymer-based medical devices designed to commercialize the next generation of stents to heal blood vessels. The company's device is a revolutionary implantable bio-absorbable polymer-based flow-diverting stent designed to gently divert blood flow to heal a weakened brain aneurysm, enabling physicians to efficiently and quickly treat patients and prevent stroke.
- Sector
- Healthcare
- HQ
- Calgary, Canada
- Founded
- 2012
- Employees
- 13
- Website
- fluidbiomed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.